



**THE FOUNDATION
FOR SECURE
MARKETS®**

#55579

Date: November 20, 2024

Subject: Exscientia plc - Contract Adjustment
Option Symbol: 11/20/2024 - EXAI remains EXAI
11/21/2024 - EXAI becomes RXRX1
Date: 11/20/2024

Contract Adjustment

Date: November 20, 2024

Option Symbol: 11/20/2024 - EXAI remains EXAI (with adjusted deliverable described below)
11/21/2024 - EXAI changes to RXRX1

Strike Divisor: 1

Contracts Multiplier: 1

New Multiplier: 100 (e.g., a premium of 1.50 yields \$150; a strike of 20 yields \$2,000.00)

New Deliverable Per Contract:

- 1) 77 Recursion Pharmaceuticals, Inc. (RXRX) Class A Common Shares
- 2) Cash in lieu of 0.29 fractional RXRX Shares, less fees, if any

Note: If the cash in lieu entitlement, if any, per RXRX1 contract is less than the applicable fees, then no cash in lieu entitlement will be associated with the RXRX1 option deliverable. Once determined, the cash in lieu of fractional share portion of the option deliverable will remain fixed and will not vary with price changes of any security.

CUSIP: RXRX: 75629V104

Pricing

Until the cash in lieu amount is determined, the underlying price for RXRX1 will be determined as follows:

$$\text{RXRX1} = 0.7729 (\text{RXRX})$$

Delayed Settlement

The RXXR component of the RXXR1 deliverable will settle through National Securities Clearing Corporation (NSCC). OCC will delay settlement of the cash portion of the RXXR1 deliverable until the cash in lieu of fractional RXXR shares, if any, is determined. Upon determination of the cash in lieu amount, OCC will require Put exercisers and Call assignees to deliver the appropriate cash amount if any.

Background

On November 12, 2024, Shareholders of Exscientia plc (EXAI) voted concerning the proposed merger with Recursion Pharmaceuticals, Inc. (RXXR). The merger was approved and consummated before the open on November 20, 2024. As a result, each existing EXAI Common Share will be converted into the right to receive 0.7729 RXXR Class A Common Shares. Cash will be paid in lieu of fractional RXXR shares. There may be ADS cancellation and distribution fees applied per the Depositary Agreement.

Disclaimer

This Information Memo provides an unofficial summary of the terms of corporate events affecting listed options or futures prepared for the convenience of market participants. OCC accepts no responsibility for the accuracy or completeness of the summary, particularly for information which may be relevant to investment decisions. Option or futures investors should independently ascertain and evaluate all information concerning this corporate event(s).

The determination to adjust options and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article VI, Sections 11 and 11A. The determination to adjust futures and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article XII, Sections 3, 4, or 4A, as applicable. For both options and futures, each adjustment decision is made on a case by case basis. Adjustment decisions are based on information available at the time and are subject to change as additional information becomes available or if there are material changes to the terms of the corporate event(s) occasioning the adjustment.

ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.

For questions regarding this memo, please email the Investor Education team at options@theocc.com. Clearing Member Firms of OCC may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email memberservices@theocc.com.